


AMENDMENTS TO THE CLAIMS:

Without prejudice or disclaimer, this listing of claims will replace all prior versions and listings of claims in the application:

1. (Previously Presented) A compound represented by the general formula (I):



wherein R¹ is a hydrogen atom, halogen atom, C1-C6 alkyl, or C1-C12 alkyloxy;

R², R³, and R⁴ are each independently a hydrogen atom, a halogen atom, C1-C15 alkyl optionally substituted with one or two substituent(s) selected from substituent group A, C2-C15 alkenyl optionally substituted with one or two substituent(s) selected from substituent group A, C2-C15 alkynyl optionally substituted with one or two substituent(s) selected from substituent group A, C3-C8 cycloalkyl, C1-C15 alkyloxy optionally substituted with one or two substituent(s) selected from substituent group A, or phenyl optionally substituted with one or two substituent(s) selected from substituent group A;

R⁵ is a hydrogen atom, a halogen atom, C1-C3 alkyl, or C1-C3 alkyloxy;

R⁶ is a hydrogen atom, a halogen atom, or C1-C3 alkyl;

R⁷ is a halogen atom or C1-C3 alkyl;

R⁸ is a halogen atom, C1-C3 alkyl, or C1-C3 alkyloxy;

R⁹ is a hydrogen atom or C1-C6 alkyl; or

R¹ and R⁵ are taken together with the adjacent carbon atoms may form a 5 to 8 membered ring which may contain a heteroatom and /or an unsaturated bond, wherein the ring may be substituted with one or two C1-C8 alkyl;

provided that when R² and R³ are a chlorine atom, R⁶ is not a hydrogen atom;

substituent group A consists of halogen atom, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, phenyl, naphthyl, pyridyl, oxolanyl, cyano, C1-C12 alkyloxy, C2-C12 alkenyloxy, C2-C12 alkynyloxy, C3-C8 cycloalkyl-C1-C8 alkyloxy, phenyl-C1-C8 alkyloxy, naphthyl-C1-C8 alkyloxy, C1-C8 alkyloxy-C1-C8 alkyloxy, (C1-C8 alkyloxy - C1-C8 alkyloxy)C1-C8 alkyloxy, di(C1-C8 alkyloxy)C1-C8 alkyloxy, oxolanyl-C1-C8 alkyloxy, haloC1-C8 alkyloxy, C3-C8 cycloalkyloxy, amino optionally substituted with C1-C8 alkyl, C1-C8 alkylthio, and C1-C8 alkylthio-C1-C8 alkyloxy;

a pharmaceutically acceptable salt, or solvate thereof.

2. (Original) A compound of claim 1, wherein both of R⁶ and R⁷ are fluorine atom or chlorine atom, a pharmaceutically acceptable salt, or solvate thereof.

3. (Original) A compound of claim 1, wherein R⁵ is a hydrogen atom or C1-C3 alkyloxy, a pharmaceutically acceptable salt, or solvate thereof.


4. (Original) A compound of claim 1, wherein R⁸ is methyl or methyloxy, a pharmaceutically acceptable salt, or solvate thereof.

5. (Original) A compound of any one of claims 1 to 4, wherein R² is C1-C15 alkyl optionally substituted with one or two substituent(s) selected from substituent group A, C2-C15 alkynyl optionally substituted with one or two substituent(s) selected from substituent group A, or C1-C15 alkyloxy optionally substituted with one or two

substituent(s) selected from substituent group A, a pharmaceutically acceptable salt, or solvate thereof.

6. (Original) A compound of any one of claims 1 to 4, wherein R^2 is C1-C12 alkyl optionally substituted with one or two C1-C8 alkyloxy, and both of R^3 and R^4 are a hydrogen atom, a pharmaceutically acceptable salt, or solvate thereof.

7. (Previously Presented) A compound represented by the general formula (II):



wherein R^A is a hydrogen atom, C1-C12 alkyloxy, C1-C8 alkyloxy-C1-C8 alkyloxy or (C1-C8 alkyloxy-C1-C8 alkyloxy)C1-C8 alkyloxy;

R^B is C1-C14 alkyl optionally substituted with one or two substituent(s) selected from substituent group B, C2-C14 alkynyl optionally substituted with one or two substituent(s) selected from substituent group B, C3-C8 cycloalkyl, C1-C14 alkyloxy optionally substituted with one or two substituent(s) selected from substituent group B, phenyl, or naphthyl;

R^C is a hydrogen atom, halogen atom, C1-C6 alkyl, or C1-C12 alkyloxy;

R^D is a hydrogen atom, halogen atom, C1-C3 alkyl, or C1-C3 alkyloxy;

R^6 and R^7 are each independently halogen atom or C1-C3 alkyl;

R^8 is halogen atom, C1-C3 alkyl, or C1-C3 alkyloxy;

substituent group B consists of halogen atom, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, phenyl, naphthyl, pyridyl, oxolanyl, cyano, C1-C8 alkyloxy, C2-C8

alkenyloxy, C2-C8 alkynyloxy, C3-C8 cycloalkyl-C1-C8 alkyloxy, phenyl-C1-C8 alkyloxy, naphthyl-C1-C8 alkyloxy, C1-C8 alkyloxy-C1-C8 alkyloxy, (C1-C8 alkyloxy-C1-C8 alkyloxy)C1-C8 alkyloxy, di(C1-C8 alkyloxy)C1-C8 alkyloxy, oxolanyl-C1-C8 alkyloxy, haloC1-C8 alkyloxy, C3-C8 cycloalkyloxy, amino optionally substituted with C1-C8 alkyl, C1-C8 alkylthio, and C1-C8 alkylthio-C1-C8 alkyloxy;
a pharmaceutically acceptable salt, or solvate thereof.

8. (Original) A compound of claim 7, wherein both of R⁶ and R⁷ are fluorine atom or chlorine atom, a pharmaceutically acceptable salt, or solvate thereof.

9. (Original) A compound of claim 7, wherein R⁸ is methyl or methyloxy, a pharmaceutically acceptable salt, or solvate thereof.


10. (Original) A compound of claim 7, wherein R^C is fluorine atom or C1-C3 alkyloxy, a pharmaceutically acceptable salt, or solvate thereof.

11. (Original) A compound of any one of claims 7 to 10, wherein R^A is C1-C8 alkyloxy; R^B is C1-C11 alkyl optionally substituted with one or two substituent(s) selected from substituent group B, or C2-C11 alkynyl optionally substituted with one or two substituent(s) selected from substituent group B, a pharmaceutically acceptable salt, or solvate thereof.

12. (Original) A compound of claim 7, wherein R^C is fluorine atom or C1-C3 alkyloxy, R^D is a hydrogen atom or C1-C3 alkyloxy, both of R⁶ and R⁷ are fluorine atom or chlorine atom, R⁸ is methyl or methyloxy, R^A is C1-C3 alkyloxy, R^B is C8-C12 alkyl optionally substituted with one or two substituent(s) selected from substituent group B, a pharmaceutically acceptable salt, or solvate thereof.

13 - 18: Cancelled.

19. (Original) A compound represented by the general formula (II-A):



wherein R^C is a hydrogen atom, a halogen atom, C1-C6 alkyl, or C1-C12 alkyloxy;

R^D is a hydrogen atom, a halogen atom, C1-C3 alkyl, or C1-C3 alkyloxy;

R^F is C1-C14 alkyl optionally substituted with one or two substituent(s) selected from substituent group D, C2-C14 alkenyl optionally substituted with one or two substituent(s) selected from substituent group D, C2-C14 alkynyl optionally substituted with one or two substituent(s) selected from substituent group D, C1-C14 alkyloxy optionally substituted with one or two substituent(s) selected from substituent group C, C3-C8 cycloalkyl, or phenyl optionally substituted with one or two substituent(s) selected from substituent group D;

R⁶ and R⁷ are each independently halogen atom or C1-C3 alkyl;

R⁸ is halogen atom, C1-C3 alkyl, or C1-C3 alkyloxy;

substituent group D consists of halogen atom, C3-C8 cycloalkyl, C3-C8 cycloalkenyl, phenyl, naphthyl, pyridyl, oxolanyl, cyano, C1-C8 alkyloxy, C2-C8 alkenyloxy, C2-C8 alkynyloxy, C3-C8 cycloalkyl-C1-C8 alkyloxy, phenyl-C1-C8 alkyloxy, naphthyl-C1-C8 alkyloxy, C1-C8 alkyloxy-C1-C8 alkyloxy, (C1-C8 alkyloxy-C1-C8 alkyloxy)C1-C8 alkyloxy, di(C1-C8 alkyloxy)C1-C8 alkyloxy, oxolanyl-C1-C8 alkyloxy, haloC1-C8 alkyloxy, C3-C8 cycloalkyloxy, amino optionally substituted with C1-C8 alkyl, C1-C8 alkylthio, and C1-C8 alkylthio-C1-C8 alkyloxy;

a pharmaceutically acceptable salt, or solvate thereof.

20. (Original) A compound of claim 19, wherein both of R⁶ and R⁷ are fluorine atom or chlorine atom, a pharmaceutically acceptable salt, or solvate thereof.

21. (Original) A compound of claim 19, wherein R⁸ is methyl or methoxy, a pharmaceutically acceptable salt, or solvate thereof.

22. (Original) A compound of claim 19, wherein R^C is fluorine atom or C1-C3 alkyloxy, a pharmaceutically acceptable salt, or solvate thereof.

23. (Previously Presented) A compound of any one of claims 19 to 22, wherein R^F is C1-C14 alkyl optionally substituted with one or two substituent(s) selected from substituent group D, C2-C14 alkynyl optionally substituted with one or two substituent(s) selected from substituent group D, or C1-C14 alkyloxy optionally substituted with one or two substituent(s) selected from substituent group D, a pharmaceutically acceptable salt, or solvate thereof.

24. (Previously Presented) A pharmaceutical composition containing a compound as an active ingredient, a pharmaceutically acceptable salt, or solvate thereof of any one of claims 1 to 4, 7 to 10, or 19 to 22.

25. (Previously Presented) A pharmaceutical composition containing a compound as an active ingredient, a pharmaceutically acceptable salt, or solvate thereof of any one of claims 1 to 4, 7 to 10, or 19 to 22 in an amount effective for exhibiting thrombopoietin receptor agonism.

26. (Previously Presented) A pharmaceutical composition containing a compound as an active ingredient, a pharmaceutically acceptable salt, or solvate


thereof of any one of claims 1 to 4, 7 to 10, or 19 to 22 in an amount effective for modifying platelet production.

27. Cancelled.

28. (Previously Presented) A method for treating or preventing hemopathy in a mammal, including a human, in need thereof, comprising


administering to said mammal a compound, a pharmaceutically acceptable salt, or solvate thereof of any one of claims 1 to 4, 7 to 10, or 19 to 22 in an amount effective amount for modifying platelet production.

29. (New) A compound of claim 1, wherein the compound is




or a pharmaceutically acceptable salt thereof.

30. (New) A compound of claim 1, wherein the compound is



or a pharmaceutically acceptable salt thereof.

31. (New) A compound of claim 1, wherein the compound is



or a pharmaceutically acceptable salt thereof.